Skip to main content

Vasculitis

Sjögren's Graduates (8.22.2025)

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article

Cardiovascular Sequelae in Adults After Kawasaki Disease

A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s. 

Read Article
TNF Inhibitors in Takayasu's Arteritis A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis. https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd
Dr. John Cush @RheumNow( View Tweet )

TNF Inhibitors in Takayasu's Arteritis

A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and  subcutaneous adalimumab in patients with Takayasu arteritis.

This multicentre study enrolled patients from Takayasu's referral centers in France, Italy, Spain, Armenia,

Read Article
2025 ACR Guidance on Diagnosis and Management of VEXAS The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management. https://t.co/KoNjOiKdTq https://t.co/9bIZgvP8kD
Dr. John Cush @RheumNow( View Tweet )

Glossary for Giant Cell Arteritis

 

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article

2025 ACR Guidance on Diagnosis and Management of VEXAS

The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management. 

VEXAS is a rare genetic disorder; the acronym stands for Vacuoles E1 enzyme X-linked

Read Article

Repurposing & Pipeline (8.8.2025)

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.

Read Article
Retrospective study of 63 pts w/ Cryoglobulinemia (essential mixed [EM], CTD-related) vasculitis (CryoVas) in remission post RTX induction. W/ 58 mos F/U Relapse rates were 23%, 42%, 71% (@ 1yr, 2yrs, 5yrs). Relapse risk w/ purpura [HR 2.2] & prior CryoVas flare (HR 1.9). https://t.co/6zGgSN8Wfe
Dr. John Cush @RheumNow( View Tweet )

2025 BSR Recommendations for ANCA-associated Vasculitis

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA)

Read Article
French retrospective observational study of Bx/CT/PET Dx of 380 #GCA pts found 7.6% (29) w/ Nl baseline CRP < 10 mg/L at Dx. GCA w/ low CRP had less fever, more ocular Dz (ant ischemic optic neuropathy 28 vs 13%), & limb claudication (24 vs. 8%) but equal relapse rates https://t.co/fPy92NjJzS
Dr. John Cush @RheumNow( View Tweet )

CKD & Osteoporosis Rx Revisited (7.25.2025)

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
Clinical Associations with Anti-RNA Polymerase III Antibodies A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome https://t.co/p1KVUFPJvN
Dr. John Cush @RheumNow( View Tweet )
Manifestations and Treatment in Relapsing Polychondritis A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease. https://t.co/Gz2qwtC4jZ https://t.co/llK9W45DlW
Dr. John Cush @RheumNow( View Tweet )
Manifestations and Treatment in Relapsing Polychondritis A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease. https://t.co/Gz2qwtC4jZ https://t.co/ZLkjNQmbRC
Dr. John Cush @RheumNow( View Tweet )

Manifestations and Treatment in Relapsing Polychondritis

A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease

Read Article

Overview of the VEXAS Syndrome

A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.

Read Article

ICYMI: EGPA in 2025

Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-

Read Article
A Review of Intracranial GCA A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n
Dr. John Cush @RheumNow( View Tweet )

PCR: Prevalence, Cost, & Risk (6.27.2025)

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article

A Review of Intracranial GCA

A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.

A systematic review included 102

Read Article
EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush @RheumNow( View Tweet )

Add-on certolizumab in pregnant women with APS

Women with antiphospholipid syndrome and lupus anti-coagulant are at high risk of developing adverse pregnancy outcomes (APO). Usual care includes low molecular weight heparin (LMWH) and low dose aspirin (LDA). Despite these therapies, APO have been reported up to 40%. An important

Read Article
Management of AAV: 1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction. 2. RTX effective for induction and maintenance, best for relapses. 3.PLEX: in RPGN pts if accesible ⚠️ risk for infection. 4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Adela Castro @AdelaCastro222( View Tweet )
Pearls on EGPA: 1. GC are mainstay for mild dz 2. Organ threatening/relapsing➡️CYP (RTX alternative) 3. W/o organ threatening➡️ anti-IL-5/IL-5R. 4. IL5i are less effective for ENT 5. Consider sx for nasal polyps. #EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Adela Castro @AdelaCastro222( View Tweet )
×